GENPHARMASEC LIMITED
Latest filings
- Dubai subsidiary renamed from DMCC to FZCO · Business Updates
- RTA cert: No physical share certificates received for demat in Q2 FY27 · Compliance
- 34th AGM voting results: all 5 resolutions passed with over 99.99 percent approval · Board & Shareholder Meetings
Snapshot
What the business is, and whether it's a good one at a fair price.
Operates as a pharmaceutical trader and distributor, with the Pharmaceuticals segment generating Rs 51.66 crore in FY26. A smaller Manufacturing & Processing line contributed Rs 3.76 crore, while a Laboratory Testing segment reported zero revenue. In July 2025, the company acquired a 70% stake in Derren Healthcare Private Limited, making it a subsidiary; Derren contributed a consolidated net loss of Rs 346.76 lakh in FY26. The company also runs a small Trading in Securities line. The cost shape is unusually thin, with materials at 2.0% of revenue, employees at 2.8%, and other operating expenses at 4.5%, fitting a low-margin distribution model rather than heavy manufacturing. Consolidated FY26 revenue stood at Rs 139.94 crore on an EBITDA margin of 3.13%, with net profit of Rs 0.56 crore.
Scorecard
Measured from the filed financials, judged against its Trading & Distributors peers · as of FY26 — not investment advice
Strengths
Nothing stands out in the filed numbers.Concerns
Charts
How has the market priced it — with filings on the timeline?
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from GENPHARMASEC LIMITED's filed financials and exchange disclosures
What does GENPHARMASEC LIMITED do?
GENPHARMASEC LIMITED is a Commercial Services & Supplies company listed on BSE.
Is GENPHARMASEC LIMITED profitable?
No. Over the trailing twelve months GENPHARMASEC LIMITED reported a net loss of ₹0.83 Cr on revenue of ₹178 Cr.
Does GENPHARMASEC LIMITED pay a dividend?
Not in the latest reported year — GENPHARMASEC LIMITED's dividend payout for FY26 was nil.
Is GENPHARMASEC LIMITED debt-free?
No. It reported borrowings of ₹33 Cr on its 31 Mar 2026 balance sheet, or net debt of ₹32 Cr after cash. Debt stands at 0.50× equity. That is higher than 74% of its 154 Trading & Distributors peers.
Is GENPHARMASEC LIMITED expensive compared with its peers?
On trailing P/E, GENPHARMASEC LIMITED ranks 70 of 130 in Trading & Distributors — cheaper than 47% of them, against an industry median of 13.9×. This is a position, not a valuation judgement.
How much does the GENPHARMASEC LIMITED share price move in a day?
On a typical session GENPHARMASEC LIMITED moves 1.75% — that is the median absolute close-to-close move across its last 267 trading days. MarketPing measures each filing's price reaction against it.
Where can I track GENPHARMASEC LIMITED's announcements?
Every NSE and BSE filing by GENPHARMASEC LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.